USFDA issues clinical hold on Covaxin new drug application: Ocugen Ruchika Sharma29 Nov 2021 11:30 AM ISTMalvern: Ocugen, Inc. has recently announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company's...
Decline in Covaxin effectiveness to 50 percent during Delta-driven COVID surge not bad: Experts Medical Dialogues Bureau28 Nov 2021 11:00 AM ISTNew Delhi: The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8% to 50% during a Delta-driven case surge in...
Government nod to commercial export of Covishield, Covaxin in view of sufficient stock Ruchika Sharma26 Nov 2021 12:43 PM ISTNew Delhi: The Union government has allowed commercial export of Covishield and Covaxin considering the sufficient stock of the COVID-19 vaccines...
Covaxin 50 percent effective against symptomatic Covid-19: Lancet study Medical Dialogues Bureau25 Nov 2021 9:15 AM ISTThe latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15May 15, who were...
Bharat Biotech says developing Covaxin was big challenge MD Bureau19 Nov 2021 1:00 PM ISTBengaluru: Bharat Biotech Director, V. Krishna Mohan, has said developing the Covaxin in "just 10 months" was an enormous challenge. Addressing...
Phase 3 data shows Covaxin 77.8 percent effective against COVID: Lancet Roshni Dhar16 Nov 2021 4:05 PM ISTBharat Biotech has recently announced that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN is peer reviewed and...
Covaxin has cellular immune memory to COVID for at least 6 months: NII Ruchika Sharma16 Nov 2021 1:21 PM ISTNew Delhi: Bharat Biotech's Covaxin has immunological memory to Covid and its variants of concern for at least up to six months, National...
Health Bulletin 13/November/2021 Roshni Dhar13 Nov 2021 6:00 PM ISTHere are Top Health stories of the dayBreach of duty in providing medical advice: Consumer Court Directs Nephrologist, Hospital to pay Rs 3 lakh...
India's Covaxin highly effective against COVID-19: Lancet study MD Editorial Team13 Nov 2021 3:26 PM ISTCovaxin, an inactivated SARS-CoV-2 vaccine, is 77.8% effective at preventing symptomatic Covid-19, find study. India: A phase three clinical...
Phase 3 data shows Covaxin 77.8 percent effective against Covid-19, says Lancet Ruchika Sharma13 Nov 2021 11:46 AM ISTHyderabad: Bharat Biotech has recently announced that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN is peer...
Ideal time for COVID booster dose is 6 months after 2nd shot: Bharat Biotech MD MD Bureau11 Nov 2021 12:30 PM ISTElla indicated that the nasal Covid vaccine could be taken instead of the second dose of Covaxin or to protect previously infected patients.
Covaxin for children under DCGI evaluation, final nod to take time: Reports Ruchika Sharma9 Nov 2021 12:40 PM ISTNew Delhi: The data for Bharat Biotech's Covaxin for Children, COVID-19 vaccine, is under evaluation and the process will take some more time for...
